Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance mesalazine (excluding Dafo RSU + KLI), ATC A07EC02 for the period 01/06/2026 - 31/05/2028 (plus option to extend once by 12 months)

Summary

The tender concerns the conclusion of a non-exclusive framework rebate agreement for medicines containing mesalazine between DAK-Gesundheit and interested pharmaceutical companies. The bidder must submit the documents required for contract conclusion or later accession by email and should note that the exact qualification and compliance requirements are set out in the tender documents.